Brian K Link Selected Research

ProMune (CpG 7909)

7/2013	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.
2/2012	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.
12/2010	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma.
10/2007	Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma.
9/2006	Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brian K Link Research Topics

Disease

32	Lymphoma (Lymphomas) 12/2022 - 02/2002
30	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2022 - 10/2007
22	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2019 - 02/2002
21	Neoplasms (Cancer) 01/2022 - 02/2002
17	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2021 - 03/2010
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2017 - 03/2005
8	Hodgkin Disease (Hodgkin's Disease) 01/2020 - 04/2006
5	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020 - 03/2004
4	Neutropenia 01/2011 - 05/2005
3	Infections 01/2016 - 10/2010
2	Fatigue 01/2022 - 03/2012
2	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 04/2020 - 12/2010
2	Leukemia 01/2020 - 04/2008
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019 - 11/2013
2	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 01/2016
2	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 01/2016 - 05/2015
2	Nausea 01/2015 - 09/2006
2	Febrile Neutropenia 04/2006 - 03/2003
1	Herpes Zoster 12/2022
1	Chronic Disease (Chronic Diseases) 01/2022
1	Burkitt Lymphoma (Burkitt's Lymphoma) 01/2020
1	Inflammation (Inflammations) 10/2019
1	Autoimmune Diseases (Autoimmune Disease) 10/2019
1	Genetic Predisposition to Disease (Genetic Predisposition) 10/2018
1	Testicular Neoplasms (Testicular Cancer) 01/2018
1	Follicular Mucinosis 04/2017
1	Necrosis 01/2017
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2017
1	Agammaglobulinemia (Hypogammaglobulinemia) 01/2016
1	Multiple Myeloma 01/2016
1	Urinary Bladder Neoplasms (Bladder Cancer) 12/2015
1	Vomiting 01/2015
1	Aspiration Pneumonia 01/2015

Drug/Important Bio-Agent (IBA)

27	Rituximab (Mabthera)FDA Link 12/2022 - 02/2002
10	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 03/2003
9	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 03/2003
9	Prednisone (Sone)FDA LinkGeneric 01/2020 - 03/2003
9	Vincristine (Oncovin)FDA LinkGeneric 01/2020 - 03/2003
8	Monoclonal AntibodiesIBA 01/2015 - 02/2002
7	AnthracyclinesIBA 01/2019 - 06/2010
6	CytokinesIBA 08/2017 - 12/2012
5	ProMune (CpG 7909)IBA 07/2013 - 09/2006
4	AntigensIBA 10/2019 - 02/2002
4	Complement System Proteins (Complement)IBA 02/2017 - 06/2008
4	Pharmaceutical PreparationsIBA 01/2015 - 02/2002
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2019 - 06/2008
3	Vitamin D FDA LinkGeneric 11/2017 - 09/2010
3	Immunoglobulins (Immunoglobulin)IBA 12/2014 - 12/2011
3	OligodeoxyribonucleotidesIBA 07/2013 - 03/2005
3	Dacarbazine (DIC)FDA LinkGeneric 05/2012 - 04/2006
3	Vinblastine (Vinblastine Sulfate)FDA Link 05/2012 - 04/2006
3	Bleomycin (Blenoxane)FDA LinkGeneric 05/2012 - 04/2006
3	CPG-oligonucleotideIBA 02/2012 - 03/2005
3	epratuzumabIBA 10/2011 - 02/2002
2	Bendamustine Hydrochloride FDA Link 12/2022 - 01/2019
2	Dihydrotachysterol (AT 10)IBA 01/2021 - 10/2019
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 02/2017
2	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 11/2017
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2018 - 10/2014
2	fludarabineIBA 05/2015 - 10/2010
2	ocaratuzumabIBA 01/2015 - 03/2012
2	Alemtuzumab (Campath)FDA Link 07/2014 - 10/2010
2	ofatumumab FDA Link 04/2012 - 06/2008
2	hydroxide ionIBA 02/2011 - 09/2010
2	Toll-Like Receptor 9IBA 12/2010 - 10/2007
2	Humanized Monoclonal AntibodiesIBA 02/2002 - 02/2002
2	Immunoconjugates (Immunoconjugate)IBA 02/2002 - 02/2002
2	apolizumabIBA 02/2002 - 02/2002
1	Alkylating AgentsIBA 04/2022
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	ORALIT (ORS)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019
1	Hemoglobins (Hemoglobin)IBA 01/2019
1	lipid-associated sialic acid (LASA)IBA 12/2018
1	Biological ProductsIBA 10/2018
1	Formaldehyde (Formol)FDA Link 01/2018
1	ParaffinIBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018
1	CalciumIBA 11/2017
1	ElementsIBA 04/2017
1	obinutuzumabIBA 02/2017
1	Intravenous Immunoglobulins (IVIG)FDA Link 01/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	cyclo(Arg-Pro) (CI 4)IBA 12/2015
1	Transcription Factors (Transcription Factor)IBA 05/2015
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 02/2015
1	ChemokinesIBA 02/2015
1	Pentostatin (Nipent)FDA LinkGeneric 07/2014
1	purineIBA 07/2014
1	ibrutinibIBA 11/2013

Therapy/Procedure

40	Therapeutics 12/2022 - 03/2003
18	Drug Therapy (Chemotherapy) 01/2020 - 03/2003
5	Immunotherapy 01/2019 - 02/2002
1	Cell Transplantation 01/2022
1	Aftercare (After-Treatment) 04/2020
1	Autologous Transplantation 01/2018
1	Induction Chemotherapy 01/2018
1	Secondary Prevention 01/2018
1	Stem Cell Transplantation 10/2017
1	Breast Implants (Breast Implant) 01/2017